P-Alaxin TS
Product Description
P-Alaxin TS is a fixed-dose combination antimalarial therapy containing Artemether and Lumefantrine, designed for the effective treatment of uncomplicated malaria caused by Plasmodium falciparum. This formulation is part of the WHO-recommended artemisinin-based combination therapies (ACTs) for malaria and is supplied as a complete treatment set (TS) for a full 3-day course.
It provides rapid parasite clearance and sustained action to prevent recurrence, making it suitable for both adults and children as prescribed.
Key Features
- Contains Artemether and Lumefantrine in fixed-dose tablets
- TS (Treatment Set) includes a full 3-day therapy course
- Rapid action against malaria parasites
- WHO-recommended first-line treatment for uncomplicated falciparum malaria
- Oral administration; easy-to-follow dosage schedule
Uses of P-Alaxin TS
- Treatment of uncomplicated malaria due to Plasmodium falciparum
- Suitable for malaria infections acquired in high-risk or endemic areas
- Helps prevent recurrence and treatment failure
Directions for Use
- Take the medication exactly as prescribed, usually over a 3-day period.
- Follow the specific dosing schedule (6-dose regimen over 60 hours).
- Take with food or a fatty meal to enhance absorption, especially for Lumefantrine.
- Do not skip doses or stop early, even if symptoms improve.
Precautions
- Not recommended in first trimester of pregnancy unless benefits outweigh risks.
- Use with caution in patients with heart conditions or electrolyte imbalances.
- Not suitable for prevention (prophylaxis) of malaria.
- Avoid use with other medications that prolong the QT interval.
- Store in a cool, dry place and keep out of reach of children.
Important Information
P-Alaxin TS is an effective first-line treatment for malaria, but it should only be used with a confirmed diagnosis and under the supervision of a qualified healthcare provider. Completion of the full course is essential to avoid resistance and ensure full recovery.